Stifel raised the firm’s price target on Exelixis (EXEL) to $38 from $36 and keeps a Hold rating on the shares. Cabometyx sales of $511M “easily beat” the firm’s and consensus estimates, notes the analyst, whose updated model mostly reflects higher FY25 estimates and the NET launch, which the firm says should prove a tailwind to FY25 top-line growth and command an additional guidance raise above the $100M announced already.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis Hold Rating: Strong Performance and Promising Pipeline Balanced by Fair Valuation
- Exelixis price target raised to $46 from $41 at Citizens JMP
- Exelixis: Strong Financial Performance and Market Position Justify Buy Rating
- Exelixis Reports Strong Q1 2025 Financial Performance
- Exelixis: Strong Financial Performance and Promising Pipeline Drive Buy Rating